Beta Bionics, Inc. (NASDAQ:BBNX) Chief Product Officer Mike Mensinger filed a Form 4 on September 3, 2026, reporting the sale of 4,375 shares of common stock on September 2, 2026, to cover tax withholding obligations tied to vesting restricted stock units.

Key Highlights

  • Reporting person: Mike Mensinger, Chief Product Officer of Beta Bionics, Inc.
  • Transaction: 4,375 shares of common stock disposed of (transaction code S) on September 2, 2026.
  • Purpose: Shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, according to the filing.
  • Weighted average price: $19.1131 per share, with a range between $18.89 and $19.545.
  • Remaining ownership: 180,040 shares of common stock directly held following the transaction.
  • Filing signed: Stephen Feider, Attorney-in-Fact, on September 3, 2026.

Beta Bionics CPO Reports RSU-Related Share Disposition

According to the Form 4 filed with the SEC on September 3, 2026, Mike Mensinger, Chief Product Officer of Beta Bionics, Inc., disposed of 4,375 shares of the company's common stock on September 2, 2026. The filing states that the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units, a common practice following RSU vesting events.

The filing discloses a weighted average sale price of $19.1131 per share. The filing further notes that the sale price ranged between $18.89 and $19.545, and states that "full information regarding the number of shares sold at each separate price will be provided" upon request by the SEC staff, the issuer, or any security holder. Following the reported transaction, Mensinger directly holds 180,040 shares of Beta Bionics common stock. No derivative securities transactions were reported in the filing.

The Form 4 was filed by one reporting person and signed by Stephen Feider as Attorney-in-Fact. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not checked on the form.

What Was Disclosed

The filing reports a single disposal of 4,375 shares of Beta Bionics common stock by its Chief Product Officer at a weighted average price of $19.1131, solely to satisfy tax withholding obligations upon RSU vesting, leaving him with 180,040 shares directly held.